Resistance to chemotherapy is a critical issue in the management of breast cancer patients. The nature of clinical drug resistance is likely to be multifactorial. However, in the last decade considerable attention has been dedicated to the role played by membrane transporter proteins belonging to the ATP binding cassette protein superfamily, and in particular by the MDR1 product P-glycoprotein (Pgp) and the multidrug resistance protein (MRP1). Heterogeneity of results is a common feature of studies evaluating the expression and prognostic role of these proteins, due to both methodological and biological factors. Nonetheless, Pgp and MRP1 are detected in a significant proportion of untreated breast cancers (on average 40 and 50% respectively, by immunohistochemistry), without a clear and consistent association with cancer stage. Exposure to chemotherapy increases the expression of both proteins. In vitro studies on primary cultures of breast cancer cells obtained at surgery consistently show an association between Pgp (protein) or MDR1 (mRNA) expression and resistance to chemotherapy. However, the correlation with clinical drug resistance is not as well defined. A stronger association of Pgp/MDR1 with response rates has been observed when expression or an increase in expression are detected immediately following chemotherapy. Correlations with prognosis appear more evident in studies using immunohistochemistry, in adjuvant and neoadjuvant settings. Evidence of clinical reversal of drug resistance by verapamil suggests a functional role of Pgp in drug resistance, although the significance of the evidence is generally weakened by poor trial designs. Future studies should take into account the multifactorial nature of drug resistance in breast cancer and use standardized approaches with adequate controls. Expression studies should be complemented by well-designed trials of drug-resistance reversal using target-specific chemosensitizing agents, and relating the results to the levels of expression of the target proteins.
Introduction
Chemotherapy plays an important role in the management of breast cancer. Adjuvant chemotherapy, in the early breast cancer setting, decreases the annual odds of recurrence by 24% and death by 15% (Early Breast Cancer Trialists' Collaborative Group 1998). In locally advanced breast cancer (Bonadonna et al. 1991 , Sapunar & Smith 2000 , neoadjuvant chemotherapy administered before surgery can reduce breast tumor size in 80-90% of breast cancer patients (Kling et al. 1997) , with pathological complete response (CR) rates that approach 20% (Moll & Chumas 1997 , Sapunar & Smith 2000 . This reduction can render operable a significant proportion of initially inoperable cancers, and allow for a more conservative surgical approach. Metastatic breast cancer also shows response rates to first-line chemotherapy of 25-55% (Winer et al. 2001) .
Taxanes and anthracyclines represent the most active agents in metastatic breast cancer, with response rates to single-agent treatment of 35-50% (Ellis et al. 2000) and 31% (Bishop et al. 1997 (Bishop et al. , 1999 respectively, in previously untreated patients. The antimetabolites 5-fluorouracil and methotrexate and the alkylating agent cyclophosphamide have been classically used for breast cancer treatment. Active agents also include vinca alkaloids, anthraquinones (mitoxantrone) and epipodophyllotoxins (etoposide) (Ellis et al. 2000) . Taxane/anthracycline combinations, among other chemotherapeutic regimens, can induce response rates in excess of 50%, with complete remissions in about 15% of cases (Miller & Sledge 1999) . In a small percentage of patients (2-3%) long-term remissions are observed (Greenberg et al. 1996) . Even after failure of first-line treatments, a significant response can be achieved with secondline anticancer regimens (Sedlacek 1990 ). Thus, even in the metastatic setting, many cancer cells are still sensitive to the cytotoxic effect of chemotherapy. However, beyond response rates, systemic treatments offer only a modest prolongation of survival for some metastatic patients and only palliation for most (Miller & Sledge 1999) . Breast cancer remains, especially in the advanced setting, largely an incurable disease.
The high percentage of non-responders and of failures following initial responses highlight the critical role played by drug resistance mechanisms in breast cancer management. Conversely, the significant number of initial responses and the impact on survival, especially in early disease, suggests that, at least initially, a limited number of mechanisms of resistance are involved. Thus, among solid cancers, breast cancer represents perhaps one of the best fields for the study of clinical drug resistance and of its reversal.
A large number of mechanisms, outlined later in this review, can cause a drug-resistant phenotype, at least in vitro. One type of mechanism is based on the function of a group of transporter proteins, able to prevent the intracellular accumulation of anticancer drugs by an efflux mechanisms. Several of these proteins belong to the ATP binding cassette (ABC) protein superfamily. Among these proteins, P-glycoprotein (Pgp) represents the one most thoroughly studied for its ability to confer a multidrug-resistant phenotype in vitro and in vivo. In the early 1990s, Pgp generated a lot of enthusiasm about its possible role in conferring drug resistance to cancer in the clinical setting and the possibility of increasing the efficacy of chemotherapy through its inhibition. Multidrug-resistance protein MRP1 was the second ABC protein to be identified as a cause of multidrug resistance. More recently, the breast cancer-resistance protein (BCRP, MXR, ABCP, ABCG2), was identified. Other ABC proteins have been initially identified for their physiological function, but subsequently have been shown to include anticancer drugs among their substrates. All of these proteins could potentially play a role in clinical drug resistance. However, the great majority of studies on the clinical role of ABC transporters have been limited to only two of these proteins: Pgp and, to a more limited extent, MRP1.
The aim of this review is to explore present knowledge about the role of ABC membrane transporters in human breast cancer drug resistance. This paper is organized into two parts. The first is aimed at providing some background on drug resistance and ABC proteins. In the second part, we provide an overview of the published studies that have addressed the expression and role of Pgp and MRP1 in breast cancer. We have focused our attention on specific questions: (i) Are ABC transporter proteins expressed in breast tumors? (ii) Does treatment affect ABC protein expression and how? 44 www.endocrinology.org (iii) Is there a correlation between ABC protein expression in breast cancer and prognosis? (iv) Does the expression of these proteins affect breast cancer response to chemotherapy? (v) What factors contribute to the heterogeneity of results between different studies? (vi) What suggestions can be given about the design of future studies? In this review, we have included clinical trials of MDR1 reversal in breast cancer. The focus is not on the results of these studies in terms of drug efficacy, but in terms of 'proof of principle' for the functional role of Pgp in causing clinical drug resistance.
This review does not provide a formal meta-analysis of the literature, as we have done previously for Pgp (Trock et al. 1997) . However, we have attempted to follow some of the same criteria that were applied to that analysis. In the section dedicated to the expression and role of ABC proteins in breast cancer, we provide a summary of the sources and methods of citation searches, the criteria we have used for exclusion and inclusion, and for data stratification, to address possible causes of heterogeneity. The same data, updated, will be part of a formal meta-analysis at a later date.
Mechanisms of drug resistance: the ABC transporters (Pgp, MRP1)
Many factors may affect the ability of anticancer drugs to kill cancer cells (Lehne et al. 1997 , Gottesman 2002 . Some of the mechanisms involved are summarized in Table 1 . Resistance may be due to pharmacological, cancer multicellular and cancer unicellular mechanisms. Pharmacological mechanisms include mechanisms that affect the ability of the drug to reach the target cell (e.g. cell metabolism and pharmacokinetics). Multicellular mechanisms are related to the three-dimensional structure of a tumor and include changes in local permeability to drug and the extracellular microenvironment (e.g. changes in pH, hypoxia) (Alabaster et al. 1989 , Teicher 1994 , and cellular mechanisms that are regulated by intercellular communication and contact (Desoize & Jardillier 2000) . Cellular mechanisms include mechanisms that affect the ability of anticancer drugs to reach the intracellular target (regulating drug influx, efflux, intracellular redistribution), mechanisms that regulate drug chemical activation/inactivation, qualitative and/or quantitative modifications to drug targets, and alterations in the molecular pathways regulating the cellular response to druginduced damage (e.g. apoptosis).
Among the cellular mechanisms that regulate the ability of an anticancer drug to reach its intracellular target, the efflux mechanism based on the function of Pgp is perhaps the most thoroughly studied. Pgp was first studied in the 1970s, when different groups described a multidrug-resistant phenotype characterized by resistance to the cytotoxic effect of multiple unrelated drugs, such as vinca alkaloids, epipodophyllotoxins, anthracyclines and actinomycin D, following cell selection with just one of these drugs (Biedler & Riehm 1970, Juliano & Ling 1976 ). This phenomenon was accompanied by decreased intracellular concentration of the target drugs due to their active efflux from cells (Riehm & Biedler 1971 , Dano 1972 , 1973 , Ling & Thompson 1974 . Later, it was defined that the same mechanism also confers resistance to taxanes and can also cause intracellular drug redistribution (Bellamy 1996) . The protein responsible for this phenotype was named Pgp and it was subsequently defined to be a 170 kDa plasma membrane glycoprotein (Juliano & Ling 1976) . The gene coding for Pgp (in humans MDR1) was isolated and cloned in the 1980s (Roninson et al. 1984 , 1986 , Gros et al. 1986 ).
In the early 1990s another membrane transporter, MRP1, was identified, characterized, and shown to confer a multidrug-resistant phenotype similar to but distinct from the one conferred by Pgp (Cole et al. 1992 , 1994 . The MRP1 mechanism of action is broadly similar to that of Pgp (active efflux of substrates from cells and intracellular redistribution) (Coley et al. 1993 , Cole et al. 1994 , Slapak et al. 1994 , Binaschi et al. 1995 , Breuninger et al. 1995 , van Luyn et al. 1998 . MRP1 confers resistance to and/ or alters intracellular accumulation of anthracyclines, epipodophyllotoxins, vinca alkaloids (Cole et al. 1994 , Breuninger et al. 1995 , Lorico et al. 1996 , Ruetz et al. 1996 , high concentrations of methotrexate (Hooijberg et al. 1999) , and actinomycin D (Lorico et al. 1996) . Unlike Pgp, MRP1 does not affect resistance to and/or transport of paclitaxel (Cole et al. 1994 , Lorico et al. 1996 , mitoxantrone (Cole et al. 1994) , arabinofuranosylcytosine (Lorico et al. 1996) or m-AMSA (amsacrine) . Evidence of the transport of colchicine, a classic substrate for Pgp, by MRP1 has been inconsistent (Cole et al. 1994 , Lorico et al. 1996 .
Pgp and MRP1 have a wide range of substrates (Table 2 ). Many MRP1 substrates are transported in the form of glucoronate, sulfate or glutathione conjugates (Leier et al. 1994 , Muller et al. 1994 , Jedlitschky et al. 1996 , Loe et al. 1996a ,b, Evers et al. 1997 , Heijn et al. 1997 , Jedlitschky et al. 1997 .
Pgp and MRP1 have physiological functions that can be inferred by their expression in normal tissues (Table 2) , the nature and range of their substrates (Table 3) , and the results of 'knock-out' and pharmacological reversal studies (Lorico et al. 1997 , Schinkel et al. 1997 , 2000 . In particular, these studies suggest that both Pgp and MRP1 play a role in protecting the organism from excessive concentrations of external as well as internal (e.g. steroids) toxins, through a regulation of their absorption, distribution (vincristine, vinblastine) Other (digoxin, Hoechst 33342, etc.) and excretion. Among other things, Pgp appears to be an important component of the blood-brain barrier (De Boer et al. 2003) .
Pgp and MRP1 are part of a larger family of proteins called the ABC protein superfamily, which in humans is known to include 48 ABC proteins (see web site: 46 www.endocrinology.org www.med.rug.nl/mdl/humanabc.htm). The ABC superfamily has been described in previous reviews (Klein et al. 1999 , Dean et al. 2001 . Based on sequence homology, ABC proteins can be grouped into seven different subfamilies (A-G). All ABC proteins share an ATP-binding domain of 200-250 amino acids (nucleotide-binding domain, NBD). The NBD unit includes two short, conserved peptide motifs (Walker A and Walker B), involved in ATP binding, and a third conserved sequence, located between the other two, that has been called the 'ABC signature', and is unique to the NBD unit.
Many of the ABC proteins are transporters and are characterized by the basic structural module 'TMD-NBD' (or NBD-TMD) consisting of one ABC unit and a hydrophobic transmembrane domain (TMD). The TMD is usually composed of six transmembrane segments (helices). To be functional, ABC transporters require a minimum of two modules, i.e. two TMDs and two NBD units. ABC proteins can be classified according to the number and arrangement of the basic structural modules (Fig. 1) . In 'full transporters' the two TMD-NBD units are part of the same polypeptide chain: (TMD-NBD) 2 . Some full transporters, e.g. several members of the ABC-C subfamily, including MRP1 (ABCC1), have a TMD 0 L 0 (TMD-NBD) 2 format. This format includes a third membrane domain (TMD 0 ), with transmembrane helices connected through a linker region (L 0 ) to the (TMD-NBD) 2 double module (Klein et al. 1999 , Borst et al. 2000 . The structure of 'half transporters' comprises only one TMD-NBD or NBD-TMD module; their activity requires aggregation in multiprotein complexes. Full transporters are usually located in the plasma membrane and half transporters in intracellular membranes, the half-transporter BCRP being one exception (Rocchi et al. 2000) .
ABC transporters exhibit ATPase activity and translocate different substrates across the cell membrane and/or between various cell compartments. Transport of substrates is ensured by a tight molecular coupling of the TMDs to the NBD units, and a positive cooperation of the two NBD units. Besides Pgp and MRP1 (renamed according to the new ABC protein nomenclature, respectively ABCB1 and ABCC1), at least another ABC protein, the half transporter BCRP (also known as MXR, ABCP and ABCG2) has been initially characterized for its ability to confer a multidrug-resistant phenotype (Allikmets et al. 1998 , Doyle et al. 1998 , Miyake et al. 1999 . Other ABC proteins have been primarily identified for other physiological functions but are able to transport anticancer substrates, and consequently represent potential drug-resistance proteins. These include the T-antigen presenting proteins TAP1/TAP2 (better known for their immunological function) (Izquierdo et al. 1996 , LankatButtgereit & Tampe 1999 , the bile salt export protein (also known as a sister of Pgp) (Childs et al. 1998 , Lecureur et al. 2000 , the canalicular multispecific organic anion transporter (cMOAT, also known as MRP2), MRP3, MRP4 and MRP5 (Borst et al. 1999, 2000) . Pgp appears approximately cylindrical in electron cryomicroscopy studies, with a diameter of about 10 nm and a depth (perpendicular to the plasma membrane) of about 8 nm and with two lobes of about 3 nm each projecting from the cytoplasmic end (Rosenberg et al. 1997) . Pgp has a central pore that, in the resting phase, is conical in shape. The base of the cone, which is open to the extracellular space, is 5 nm wide (Rosenberg et al. 1997 , Loo & Clarke 2001a . The diameter of the pore is 0.9-2.5 nm at mid-level through the www.endocrinology.org 47 cell membrane and its cytoplasmic end corresponds to the apex of the cone and is virtually closed (Loo & Clarke 2001a) . The Pgp substrate binding area is located around the mid-level of the pore (Loo & Clarke 1997 , 1999a , 2000 .
The results of cysteine scanning mutagenesis and crosslinking studies are consistent with a 'cyclone model' of Pgp, whereas the two homologous halves of Pgp are arranged in the cell membrane in an antiparallel fashion, with transmembrane segments 4-6 and 10-12 more directly contributing to delimit Pgp's central pore (Loo & Clarke 1999b) . Pgp substrates most likely diffuse from the inner leaflet of the cell membrane (hydrophobic vacuum cleaner model) (Raviv 1990 , Higgins 1992 , and between Pgp's transmembrane α-helices to the Pgp's substrate binding area located inside the pore, where they interact mostly with non-polar amino acids (Loo & Clarke 1997 , 1999a , 2000 . Interaction with the binding site in the presence of ATP induces ATP hydrolysis, followed by a rearrangement of the protein conformation: movement of Pgp's N-terminal and C-terminal halves in opposite directions closes the pore (Loo & Clarke 2002) , while rotation of the transmembrane α-helices (Loo & Clarke 2001b ) may contribute to decrease the affinity of the site for the substrates. Ultimately, the substrate is pushed either to the extracellular phase ('hydrophobic vacuum cleaner' model) or to the membrane's outer leaflet ('flippase model').
Two-dimensional crystal data from purified MRP1 have been obtained and evaluated by electron microscopy, revealing an overall dimension of 8-10 nm and the association of MRP1 in dimers (Rosenberg et al. 2001) . Infrared spectroscopy has revealed a secondary structure made of 46% α-helix, 26% β-sheet, 12% β-turns and 17% random coil. The secondary structure of MRP1 is not changed by binding of ATP, its hydrolysis, or GSH-dependent transport of substrates. Binding of ATP (but not its hydrolysis), changes the protein's tertiary structure. The tertiary structure is then reversed to its original conformation when the hydrolyzed inorganic phosphate is released. Binding of substrates modifies the tertiary structure of MRP1's TMDs, but modification of the tertiary structure of the cytoplasmic domains with an associated increase in ATP binding and hydrolysis requires the presence of glutathione (Manciu et al. 2000 (Manciu et al. , 2002 . Transmembrane segments 10-11, in membranespanning domain 1 (MSD 1 ), and transmembrane segments 16-17, in MSD 2 , appear to be particularly critical for substrate interaction, as demonstrated by both mutation and photo-affinity labeling studies (Daoud et al. 2001 , Ito et al. 2001 , Mao et al. 2002 .
Expression and role of Pgp and MRP1 in breast cancer
Previously, we completed a formal meta-analysis of published data on the expression and functional significance of MDR1/Pgp in breast cancer (Trock et al. 1997) . Here, we provide an updated review of both Pgp/MDR1 and MRP1 and their clinical role in breast cancer. We have not carried out a formal meta-analysis of published data. To obtain a more synthetic and encompassing view of results, whenever feasible, we have pooled the data from comparable studies. Papers often report different levels of positivity for protein expression. In some studies, specimens have been defined as positive even if Pgp was detected only in the cytoplasm or in a small number of cells. For each study, we used the data 48 www.endocrinology.org corresponding to the minimum definition of positivity provided by the authors. For immunohistochemical (IHC) evaluations, when more than one antibody was used we considered a case as positive when immunostained by any of the antibodies. In studies where more than one antibody was used, we have considered the results of the antibodies that gave the highest sensitivity. Where possible, we have also calculated the average detection rate across studies that included 20 patients or more per target subgroup. In the previous metaanalysis (Trock et al. 1997) The studies considered in this review represent the results of original research involving measurement of Pgp or MRP1 mRNA and/or protein expression in human breast cancers. Gene amplification studies were not included. Only peer-reviewed publications were considered (with the exception of a study whose results were presented as a letter to Lancet (Nooter et al. 1997a) ). Reviews were excluded as a source of data but were used as a source of references, as were data publications in a language other than English. Where the same study was reported in different papers, only the most recent publication was considered. We cannot exclude the possibility that some cases were included in different papers from the same research group.
Pgp and breast cancer

Pgp/MDR1 expression in untreated breast cancer and normal tissues
In almost all studies on expression in non-neoplastic breast tissue, Pgp/MDR1 could be detected in normal breast tissues at both the protein and mRNA level. Pgp was readily detected by IHC in four studies (Cordon-Cardo et al. 1990 , Ro et al. 1990 , van der Valk et al. 1990 , Scala et al. 1995 . Van der Valk et al. (1990) found Pgp expression to be weak and confined to breast epithelial cells, while absent from the stroma. Scala et al. (1995) observed Pgp expression in 21/24 (88%) normal or benign breast tissues. Pgp expression was confined to the luminal surface of ductal epithelium, where it was located in cell membranes. Ro et al. (1990) found Pgp expressed in the adjacent normal or hyperplastic tissue of 67% of 40 locally advanced breast cancers. These authors also reported Pgp expression in 69% of the corresponding cancer tissues. In 35% of cases expression in cancerous and normal tissues was discrepant. Only one study used an immunoblot approach: no Pgp could be detected in five healthy breast tissue samples, as compared with a detection rate of 10/34 in untreated breast cancers (Sanfilippo et al. 1991) . At the mRNA level, an RT-PCR study showed higher average levels in the neoplastic as compared with the associated normal tissue component of 40 locally advanced breast cancers before treatment with neoadjuvant chemotherapy. Following treatment, the significance of this difference was lost, largely due to a higher level of induction of MDR1 in benign tissues (Arnal et al. 2000) .
Expression of Pgp/MDR1 protein in untreated breast cancer has been most often evaluated by IHC. We have found 29 papers reporting the results of IHC evaluations of Pgp expression in previously untreated patients. The data from these papers are summarized in Tables 4-6 . When all data are pooled, the detection rate of Pgp by IHC is 40% (744/1840) in untreated patients. Overall, detection in these studies ranged from 0 (Yang et al. 1999) to 100% (Del Vecchio et al. 1997) . When only studies with more than 20 patients are considered (28 studies), the average rate of detection is 45.9% (95% confidence interval: 35.6-56.2).
Various different antibodies have been used for Pgp detection in breast cancer. Six different monoclonal antibodies were used on breast cancer tissues: JSB-1, C219, MRK16, C494, 4E3 and UIC2. The characteristics of these antibodies have been previously reviewed (van der Heyden et al. 1995 , Beck et al. 1996 . JSB-1 recognizes a cytoplasmic epitope of Pgp and does not cross-react with MDR3 or with the heavy chain of muscle myosin, as does the C219 antibody. The 16 studies using JSB-1 as the primary antibody show a pooled detection rate of 34% (361/1075). C219 also recognizes a cytoplasmic epitope and it has been the second most frequently used antibody for the detection of Pgp in breast cancer (eight studies). In studies where only C219 was used, it detected Pgp in 111/321 cases (35%). MRK16 (seven studies), which recognizes an external epitope and does not cross-react with MDR3, gave a pooled detection rate of 36% (110/307). Polyclonal antibodies had a higher detection rate (59/94, or 63%).
One of the recommendations from the St Jude MDR Workshop on Methods to Detect Pgp-associated Multidrug Resistance (Beck et al. 1996) was that more than one antibody be used for Pgp detection. Eight studies on Pgp expression in untreated breast cancer used more than one antibody www.endocrinology.org 49 (Wishart 1990 et al., De la Torre et al. 1994 , Decker et al. 1995 , Linn et al. 1995 , Wang et al. 1997 , Gago et al. 1998 , Yang et al. 1999 . Of these, six studies used two antibodies, and two (Linn et al. 1995 , Wang et al. 1997 ) used three antibodies. Different antibodies were used on separate samples, with one exception where two antibodies were used as a 'cocktail' (Gago et al. 1998) . Only four of the above papers report the results in a way that allowed us to calculate the detection rate when positivity is defined as staining with both of two antibodies: the pooled rate is 24% (or 30/124) (Wishart et al. 1990 , De la Torre et al. 1994 , Decker et al. 1995 , Wang et al. 1997 . Unfortunately, there are not enough data available to allow an evaluation of whether this more stringent definition of positivity improves the correlation of Pgp expression with other clinical and pathological parameters, including treatment outcome.
A study by Del Vecchio et al. (1997) represents a single instance in which in vitro quantitative autoradiography, with 125 I-MRK16 antibody, was used for the in situ detection of Pgp expression. In this study, Pgp was detected in all 27 cases studied (100%).
Detection of Pgp-positive (Pgp + ) cells by fluorescence-activated cell sorting has been used in two separate studies (Brotherick et al. 1996 , Gregorcyk et al. 1996 . Only the paper by Gregorcyk et al. provides an actual Pgp detection rate: 43.6% (24/55) of untreated breast cancers.
Protein expression has also been evaluated by a 'bulk' method, such as Western blot, with a pooled rate of detection of 32.6% (80/245) across four studies. This pooled number does not reflect the difference in detection reported in an early study by Merkel et al. (1989) , using the C219 antibody (where Pgp was detected in 0/125 cases), and a later study by Buser et al. (1997) , who detected Pgp in 70/84 cases using a polyclonal antibody.
Detection of Pgp/MDR1 mRNA by RT-PCR studies shows a higher level of sensitivity than IHC. Across 12 studies, MDR1 expression was detected in 334/531 cases (63%) ( Table 5) . Detection rates range from 0 to 100%. Earlier evaluations of MDR1 mRNA levels had been based on the use Northern blotting techniques, yielding a pooled detection rate of 28% (52/185) across four studies (Table 5) .
Four studies have considered the agreement between IHC-and RT-PCR-based evaluations of MDR1/Pgp expression in untreated breast cancer. Two studies showed a concordance rate of 73% (Chevillard et al. 1996 , Filipits et al. 1996 . However, Hegewisch-Becker et al. (1998) found a wider disagreement between the two techniques, with a concordance rate of only 34%. Discrepancy was interpreted as at least partly due to lymphocyte contamination in the RT-PCR samples. A concordance rate as low as 31% was also reported by Wang et al. (1997) , although this might simply reflect the difference in sensitivity between the two techniques. Table 4 Pgp expression in untreated breast cancer. The table includes data only from those studies providing the ratio of positive/total cases. Studies where previous treatment status was uncertain were excluded. For IHC-based studies, when more than one antibody was used, any positivity (with either) would be considered as a sign of overall positivity. Where different levels of positivity were provided, we used the data for the lowest provided cut-off of positivity
Reference
Setting Antibodies Pgp + /total IHC studies Salmon et al. (1989) Metastatic JSB-1 1/5 Sugawara et al. (1990) Not described MRK16 2/20 Wishart et al. (1990) Operable* C219, MRK16 23/29 Ro et al. (1990) Locally advanced C219 6/9 Verrelle et al. (1991) Locally advanced, metastatic C494 14/17, 3/3 Koh et al. (1992) Locally advanced JSB-1 1/11 Charpin et al. (1994) Not described JSB-1 113/213 De la Torre et al. (1994) Operable C219, MRK16 6/41 Keen et al. (1994) Operable Polyclonal 14/43 Veneroni et al. (1994) Locally advanced C219 18/39 Decker et al. (1995) Locally advanced (w/o mts***) C219, C494, polyclonal 8/9 Locally advanced (with mts) 1/2 Metastatic (from mts) 8/9 He et al. (1995) Operable C219 23/50 Schneider & Romero (1995) Mixed Polyclonal 28/31 Seymour et al. (1995) Locally advanced C219 18/40 Chevillard et al. (1996) Locally advanced C219, JSB1, C494 9/54 Filipits et al. (1996) Operable C219 36/63 Bargou et al. (1997) (Tables 4, 5 and 7) . The average detection rates in studies that included 20 cases or more were respectively 40.8% (95% confidence interval: 26.0-55.6; eight studies) and 42.7% (95% confidence interval: 24.5-60.9; nine studies). Only one study directly compared Pgp expression at the early and at the advanced stage: using IHC, Linn et al. (1997) detected a statistically significant difference in Pgp expression between early operable (2/20, 10%) and locally advanced breast cancers (18/30, 60%). Four studies considered the correlation between Pgp expression and T staging (De La Torre et al. 1994 , Schneider & Romero 1995 , Sun et al. 2000 , Schneider et al. 2001 . Table 6 Pgp expression in untreated breast cancer -summary. Some studies used more than one approach to Pgp detection (Chevillard 1996 , Fillipits et al. 1996 , Hegewisch-Becker et al. 1998 , Merkel et al. 1989 , Wang et al. 1997 , Yang et al. 1999 . Only the approach that was used on most cases was considered when calculating the expression of Pgp across all assays When the results of these studies are pooled, Pgp appears to be expressed in 23% (5/22) of T1 (tumors 2 cm or less), 47% (30/64) of T2 (between 2 and 5 cm), 50% (10/20) of T3 (more than 5 cm in size), and 42% (5/12) of T4 cases (tumors with a direct extension to chest wall or skin). These data appear to suggest that untreated tumors larger than 2 cm are more likely to express Pgp than smaller tumors.
Overall the results from six IHC, one flow cytometric, and one Western blot study are not supportive of a correlation between Pgp expression and nodal status. This is partly due to the high heterogeneity of results and the low number of cases in certain subgroups. Two of the IHC studies (Ro et al. 1990 , Charpin et al. 1994 , and the isolated flow cytometric study (Brotherick et al. 1996) found no correlation between nodal status and Pgp expression. Buser et al. (1997) detected Pgp by Western blot in 20/26 (78%) node-negative and in 26/30 (87%) node-positive early breast cancer cases. In the locally advanced setting, Pgp was expressed respectively in two of four (50%) node-negative and in 26/30 nodepositive cases.
The small number of node-negative cases in the locally advanced setting does not allow any conclusion as to the rate of Pgp expression. A similar problem affects the evaluation of the study by De La Torre et al. (1994) , who reported a higher incidence of nodal involvement in Pgp-negative (Pgp −, 23/35 cases, or 65%) than in Pgp + cases (one of six, or 17%). Two studies (Schneider & Romero 1995 , Sun et al. 2000 considered Pgp expression's correlation with N staging. Pooling the data from the two studies provides what appears to be a certain inverse correlation between Pgp expression and N stage: Pgp expression is observed in 17/21 (81%) N0 cases, 13/19 (68.4%) N1 cases, and 6/15 (40%) N2 cases. Another study, however, showed that 14/23 (60.9%) Pgp + and 14/27 (40.7%) Pgp − breast cancers have more than four axillary lymph nodes involved (He et al. 1995) .
Data on Pgp expression in untreated metastatic breast cancer are infrequent. All studies are based on the use of IHC. Four of these studies compare the expression of Pgp in the primary lesion of metastatic and non-metastatic patients. When the results of these four studies are pooled, no difference in Pgp expression is observed between metastatic and non-metastatic cases, Pgp being detected in 55/74 (74.3%) non-metastatic vs 16/22 (72.7%) metastatic cases (Verrelle et al. 1991 , Decker et al. 1995 , Schneider & Romero 1995 , Sun et al. 2000 . Most of the M0 cases were represented by cancers with primaries larger than 2 cm, if not locally advanced. One study compared the expression of Pgp in the primary lesions of non-metastatic cancers and in the metastases of metastatic cancers (apparently, all untreated): Pgp was detected in 7/12 metastatic samples (58%) and in only 27/92 (29%) primary cancers (P = 0.055) (Linn et al. 1995) . The results of this study suggest an increased expression of Pgp in metastases as compared with the primary sites. However, to the best of our knowledge, expression of Pgp has never been compared in the primary and metastatic sites of the same patients.
In considering MDR1 mRNA expression and breast cancer stage, there is no difference in pooled MDR1 mRNA detection rates between primary operable (183/314 cases, or 58%, in five studies) and locally advanced cases (101/165 cases, or 61%, in three studies) from studies where RT-PCR was used (Chevillard et al. 1996 , Filipits et al. 1996 , O'Driscoll et al. 1996 , Wang et al. 1997 , Hegewisch-Becker et al. 1998 , Lacave et al. 1998 , Yang et al. 1999 , Arnal et al. 2000 ( Table 7) .
As observed in IHC studies, data on the correlation between MDR1 mRNA and nodal status appear highly heterogeneous and inconclusive. No difference in MDR1 mRNA levels or in the percentage of MDR1 + and MDR1 − cases (as evaluated by slot blot analysis) was observed in cases with different nodal stages (N0, N1 and N2) (Wallner et al. 1991) . In an RT-PCR study, MDR1 mRNA levels were not different in node-positive and node-negative cases (Lacave et al. 1998) . In another RT-PCR study, levels of MDR1 mRNA seem to decrease from N0 to N2 cases, but the differences are not statistically significant (Dexter et al. 1998) . The only statistically significant difference was reported by Schneider et al. (2001) who observed a higher rate of nodal involvement in MDR1 + (18/22; 81.8%) than in MDR1 − cases (13/24; 54.2%).
Only one study compared MDR1 mRNA levels in untreated metastatic and non-metastatic breast cancer. The 52 www.endocrinology.org results of this study show that MDR1 mRNA levels measured by RT-PCR at the primary site, are lower in metastatic disease than in non-metastatic disease. However, the evaluation included only four metastatic cases and the differences were not significant (Dexter et al. 1998) .
Effect of chemotherapy on Pgp expression
Both the processes of induction and of selection could be involved in an effect of chemotherapy on Pgp expression. In vitro studies have shown that treatment of neoplastic cells with chemotherapeutic agents can induce the expression of Pgp (Chaudhary & Roninson 1993) . This induction appears to be independent of whether the anticancer drugs are substrates for Pgp, and may be part of a response to different stress stimuli, including irradiation, genotoxic stress and inflammation (Sukhai & Piquette-Miller 2000) . Conversely, treatment with anticancer drugs to which Pgp confers resistance would be expected to enrich cancer in Pgp + cells by a process of selection and should be specific for drugs that are MDR1 substrates.
Twenty-six studies have evaluated the expression of Pgp following either recent or remote anticancer treatment (Tables 8a-d) , mostly including MDR1 substrates. IHC evaluations detected Pgp in 46% of previously treated cases (256/556; 19 studies), as compared with the 41% detection rate reported for untreated cases (see above). When only those cases are included whose treatment certainly included MDR1 substrates (i.e. also excluding studies where treatment was not defined), Pgp appears to be detected by IHC in 172/ 329 cases (52%, across 16 studies). Pgp is detected in only 37% (84/227, four studies) of those cases whose treatment was either not described or did not include MDR1 substrates. The rate of IHC detection appears be lower in remotely (42/ 117, or 36%, across six studies) than in recently treated cancer (170/306, or 56%, across 11 studies), suggesting that the effect of chemotherapy is transient. cases, in five studies) of treated vs about 61% of untreated cases. Western blotting detected Pgp in 9/16 (56%) cases in two small studies (Merkel et al. 1989 , Sanfilippo et al. 1991 , while two small Northern blotting studies did not detect MDR1 mRNA in any of 16 patients (Merkel et al. 1989 , Hennequin et al. 1993 .
A more adequate evaluation of the effect of chemotherapy may be obtained in studies where the same cancers are evaluated for Pgp expression before and after chemotherapy. These studies represent only a fraction of those considered above, and they have been carried out almost exclusively in patients being treated with neoadjuvant chemotherapy for locally advanced breast cancer. The results of these studies are summarized in Table 9 . In seven IHC studies, involving 176 patients, Pgp was detected in 71 cases (40%) before and in 102 cases (58%) after systemic treatment (Ro et al. 1990 , Koh et al. 1992 , Keen et al. 1994 , Decker et al. 1995 , Chevillard et al. 1996 , Chung et al. 1997 the rates of detection of MDR1 mRNA were 50% (57/113) before and 73% (82/113) after treatment with MDR1 substrate-containing regimens, with an induction rate (change from negative to positive) of 45% (Chevillard et al. 1996 , Arnal et al. 2000 . One study of particular interest is that by Chevillard et al. (1996) . In this investigation, The two chemotherapy regimens used in this study had somewhat different effects on the rapidity of induction of MDR1 expression. Induction by the doxorubicin-containing regimen was evident in 18/50 cases (36%) on day 8 and 24/ 50 cases (48%) on day 28. The thiotepa-containing regimen induced MDR1 in ten (43%) and in 11 (48%) out of 23 cases on day 8 and 28 respectively. Changes in the levels of protein expression were similar to those observed for MDR1 mRNA expression. Hence, the level of Pgp induction is comparable for both regimens, independent of the presence of MDR1 substrates. However, as the results of this study show, induction following treatment with doxorubicin may occur more slowly than after treatment with thiotepa. The apparent independence of the observed effect from the presence of MDR1 anticancer drugs would appear to support a non-specific Pgp/ MDR1 induction, rather than a selection effect.
Association of Pgp expression with other clinical, pathological and molecular markers
The expression of MDR1/Pgp may correlate with that of other known clinical, pathological, and molecular markers. Parameters evaluated for their association with Pgp expression include, among others, tumor grade, ploidy, histology, estrogen receptor (ER) and progesterone receptor (PgR), and p53.
With tumor grade, overall, there is no consistent or convincing evidence for a significant correlation between MDR1 expression and grade. Ferrero et al. (2000) , measuring MDR1 expression by RT-PCR, reported a modest association of MDR1 expression with grade 1 cancers. A similar trend is evident from the RT-PCR data reported by Beck et al. (1998) . In contrast, the opposite trend was observed in two additional studies, one using RT-PCR (Lacave et al. 1998) , and the other using IHC (De la Torre et al. 1994) . Finally, www.endocrinology.org no association with tumor grade was observed in four studies, two of which used IHC, one flow cytometry and one RT-PCR, to detect Pgp/MDR1expression (Charpin et al. 1994 , Brotherick et al. 1996 , Chevillard et al. 1997 , Dexter et al. 1998 .
For ploidy, a correlation between Pgp/MDR1 − status and aneuploidy is supported by two out of three studies. Chevillard et al. (1997) observed a significant correlation between MDR1 negativity and aneuploidy in a series of locally advanced breast cancers, evaluated before neoadjuvant chemotherapy. A similar trend can be observed in the data reported by Lacave et al. (1998) . However, in the latter study the correlation did not reach statistical significance. In a third study, De la Torre et al. (1994) found no difference in ploidy between Pgp + and Pgp − cases. In their study, diploid cancers represented 31% of 35 Pgp − cases, and 33% of six Pgp + cases.
In comparison with histology, two RT-PCR-based studies report a higher incidence of MDR1 expression in lobular than in ductal breast carcinomas. In the first, MDR1 mRNA was detected in three of four cases of lobular carcinoma and in 15/60 ductal carcinomas. Notwithstanding the small numbers, this difference was statistically significant (Chevillard et al. 1997) . Similarly, the second study reported significantly higher levels of MDR1 mRNA in lobular than in ductal carcinomas (Dexter et al. 1998) . In contrast, Lacave et al. (1998) found no difference in MDR1 expression between 63 cases of ductal carcinomas and ten cases of lobular carcinomas.
In receptor studies, overall, there is no clear indication of a correlation between Pgp and ER, and between Pgp and PgR expression. A direct correlation between ER and Pgp expression was observed in two studies. An IHC study of 101 biopsies from accessible recurrent or metastatic sites found a significant association between ER and Pgp positivity. ER + tumors were more often Pgp + (69%) than ER − tumors (46%) (Seymour et al. 1995) . In the second study, evaluation by RT-PCR reported MDR1 to be expressed at higher levels in ER + (9.22 molecules/µg × 10 6 ) than in ER − cases (4.00 molecules/µg × 10 6 ) but the difference was not statistically significant (Dexter et al. 1998) . By contrast, an inverse correlation is suggested by the results of two other IHCbased studies. In the first of these studies it was observed that ER − tumors were more often Pgp + (30%) than Pgp − (15%), the difference being statistically significant (Charpin et al. 1994) . A similar trend was reported by Wang et al. (1997) , who reported Pgp positivity in 15% (4/26) of ER + and 39% (7/18) of ER − cases with borderline statistical significance (P = 0.078).
For PgR, a trend to a direct correlation with Pgp is suggested by the RT-PCR-based study by Dexter et al. (1998) and the IHC study by Seymour et al. (1995) . However, a statistically significant inverse correlation between PgR and Pgp proteins was reported by Wang et al. (1997) .
We found seven additional studies reporting no correlation between Pgp expression and expression of ER and/or PgR (Ro et al. 1990 , Wallner et al. 1991 , De la Torre et al. 1994 , He et al. 1995 , Brotherick et al. 1996 , Lacave et al. 1998 , Ferrero et al. 2000 .
Turning to mutant p53 proteins, these are often more stable and are readily detected by IHC methods (Elledge & Allred 1998) . Most studies show a direct correlation between Pgp and p53. In a group of 15 archival breast cancer specimens, overexpression of Pgp was most often accompanied by high levels of p53 (Bodey et al. 1997) . In another IHC study, p53 was positive in 88/113 (78%) of Pgp + cases, with cells staining with both Pgp and p53 antibodies mostly coinciding (Charpin et al. 1994) . Linn et al. (1996) reported a statistically significant correlation between IHC detected Pgp and nuclear accumulation of p53, with Pgp staining in 5/26 p53 − tumors (19%) and in 15/24 p53 + cases (62%). Similarly, Schneider & Romero (1995) observed cell membrane staining for Pgp in 8/22 p53 − (36%) and in six out of nine p53 + breast cancers (67%)
In contrast to IHC, which is expected to detect mutant forms of p53, RT-PCR has been used to quantitate the expression of normal p53. Ferrero et al. (2000) observed a slight but significant inverse correlation between cytosolic p53 levels and MDR1 expression as detected by RT-PCR in 85 node-positive patients undergoing surgery and adjuvant treatment. Another study failed to detect any association between p53 mutations and de novo expression of MDR1 in 64 patients undergoing neoadjuvant chemotherapy (Chevillard et al. 1997) .
Overall, with the only exception of the study by Chevillard et al. (1997) , these studies are consistent with basic research studies indicating the ability of normal p53 to repress the transcription of MDR1 and conversely an increase in the expression of MDR1 in the presence of p53 mutants (Goldsmith et al. 1995 , Chevillard et al. 1997 , Thottassery et al. 1997 . However, these basic research data have sometimes been contradicted by the results of other studies (Li et al. 1997 , Zhou & Kuo 1998 ). Both at the in vitro and at the clinical level, the relationship between p53 and MDR1/Pgp is likely to be complex and affected by both the kind of p53 mutations and the particular cell signaling environment.
Clinical role of Pgp
Ultimately, the purpose of measuring Pgp expression is in its potential clinical role, either as a marker of prognosis and/or as a predictor of response to treatment. If Pgp plays such a role, knowledge of its expression may be used for the selection of more effective treatments, for example including anticancer drugs that are not substrates for Pgp, or inhibitors of Pgp function.
The clinical role of a drug-resistance protein can be evaluated in different ways. To support the specific protein's role 56 www.endocrinology.org as a cause of drug resistance, correlative clinical studies should demonstrate a significant relationship between the protein (or its mRNA) expression and resistance to systemic treatments that include drugs that are substrates for the drugresistance proteins. Evaluations in the neoadjuvant setting can consider expression before, during and after treatment, and by comparison, the amount of induction. Expression in this setting and at these different times in relation to treatment, can be compared with response rates (clinical, pathological) as well as survival parameters. Studies in the adjuvant setting allow evaluation only before treatment and its correlation with longer-term outcomes (survival and disease-free survival (DFS)), but have the potential advantage of a lower number of coexpressed and possibly redundant mechanisms of resistance. Conversely, in the advanced setting, the role of a specific protein is more likely to be masked by the multifactoriality of drug resistance.
Clinical trials of drug resistance reversal represent the ultimate test of a protein's functional role in clinical drug resistance. Such a role may be established by randomized or cross-over trials that can demonstrate statistically significant cancer sensitization. To be meaningful, this sensitization should be specific to drugs which are the resistance protein's substrates, it should be obtained with chemosensitizing agents that specifically target the protein, and specifically in cancers where it is expressed.
Pgp/MDR1 expression and response to treatment
Most published studies relating MDR1/Pgp expression to prognosis in the adjuvant setting have used IHC to detect Pgp. The results of most evaluations support a correlation between Pgp expression and prognosis.
Among 205 patients undergoing a variety of treatments, Gago et al. (1998) observed a higher incidence of subsequent metastatic recurrences in the group of patients whose primary tumor had been Pgp + than in those with Pgp − tumors (27 vs 16% respectively). The prognostic association was statistically significant by univariate but not by multivariate analysis. The correlation of Pgp expression with recurrence rates did not consider the kind of treatment, whether or not MDR1 substrates were used.
In another study, evaluating 50 patients treated with MDR1 substrate-containing regimens (doxorubicin or vincristine), overall survival (OS) was significantly better for 27 Pgp − than for 23 Pgp + patients, survival rates at 60 months being 70 and 26% respectively. Statistical significance of the difference was confirmed by multivariate analysis (He et al. 1995) . Linn et al. (1995) compared Pgp − breast cancers (73 cases) with cancers where both the cancer cell and the intermixed desmoplastic stroma components stained positive for Pgp (four cases). This study demonstrated differences at 3 years in both DFS (respectively 80 and 25%) and OS rates (respectively 92 and 25%). These differences are significant by univariate analysis. Interestingly, when patients were compared on the basis of Pgp expression only in cancer cells, there was no difference in DFS, and a much smaller difference in OS. It is difficult to relate this prognostic impact to an anticancer drug treatment, as this was limited to a fraction of the patients and it was quite heterogeneous: of 27 patients treated in the adjuvant setting, 11 were treated with a CMF (cyclophosphamide, methotrexate and fluorouracil) regimen, only one with a regimen containing an MDR1 substrate drug, and 15 were treated with tamoxifen or a chemo-hormonal combination. Interestingly, the clearest negative prognostic impact of Pgp was on the group of tamoxifen-treated patients.
In the only study where MDR1 mRNA expression was evaluated by RT-PCR, no significant correlation was found between MDR1 mRNA levels and progression-free survival or OS of 85 node-positive patients treated with anthracycline-containing adjuvant regimens (Ferrero et al. 2000) .
Effect of pre-and post-treatment Pgp expression on the response of locally advanced breast cancer to neoadjuvant chemotherapy is summarized in Table 10 , which shows the results of IHC studies evaluating the correlation of pre-and post-treatment Pgp expression with the rates of response to neoadjuvant chemotherapy in locally advanced breast cancers.
Comparing pooled data, the presence of detectable amounts of Pgp before treatment appears to correlate with the CR rate (14%, or 10/72 in Pgp +, vs 36%, 40/112 in Pgp − cases), but not the OR rate (about 63% in both cases, or 34/54 in Pgp + vs 60/95 in Pgp −, across seven studies) following treatments containing anticancer drugs that are MDR1 substrates (Verrelle et al. 1991 , Decker et al. 1995 , Chevillard et al. 1996 , Chung et al. 1997 , Wang et al. 1997 , Honkoop et al. 1998 , Bottini et al. 2000 , Faneyte et al. 2001 , Schneider et al. 2001 . In the only study considering the response to non-MDR1 chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil, plus tamoxifen), nearly identical percentages of complete responders were observed (respectively 29 and 30%) in Pgp + and Pgp − cancers (Bottini et al. 2000) . In terms of correlation with survival parameters, the published data show results that range from none to a significant survival advantage for Pgp − cases. Verrelle et al. (1991) observed that progression-free survival was significantly worse in the seven patients (out of a total of 17) expressing the highest levels of Pgp (more than 75% cells staining strongly for Pgp), following neoadjuvant treatment with a chemotherapy regimen containing MDR1 drugs (doxorubicin and vincristine). The study by Vargas-Roig et al. (1999) , who used a quite stringent criterion for Pgp positivity (more than 66% of cancer cells staining positive), reports 22 Pgp + cases out of a total of 37. Following neoadjuvant treatment with doxorubicin-or epirubicin-containing chemotherapy, there was no significant difference in OS and DFS based on Pgp status, although, in both cases a trend for a worse survival can be noticed for Pgp + cases. Honkoop et al. (1998) observed no significant difference in DFS and OS in patients treated with doxorubicin and cyclophosphamide, based on pre-treatment Pgp status only (Pgp + status being defined as the presence of < 20% positively stained cells; 9/27 cases were considered positive). In the same study, nuclear accumulation of p53 did not appear to have an impact on prognosis. However, when cancers were positive for both Pgp and p53, both DFS and OS were significantly worse.
Pgp expression after treatment with anthracyclinecontaining chemotherapy appears to be more predictive of response than its expression before chemotherapy (Ro et al. 1990 , Koh et al. 1992 , Botti et al. 1993 , Decker et al. 1995 , Chevillard et al. 1996 , Chung et al. 1997 (Table 10 ). The pooled objective response rates are 93% (56/60 patients) among Pgp − cases vs 52% (45/82) among Pgp + cases. Pooled CR rates are respectively 17 and 7.5%. In terms of impact on survival parameters, a statistically significant association between post-chemotherapy Pgp expression and DFS is suggested by one IHC study (Botti et al. 1993) . As in the case of pre-treatment expression, in the study by Honkoop et al. (1998) an association of post-treatment Pgp expression with OS was significant only when combined with positivity for p53.
The apparently higher predictive value of Pgp expression, when it is detected after chemotherapy, suggests the possibility that inducibility of Pgp expression by treatment may be a more important predictor of response to chemotherapy than measuring only Pgp expression, whether before or after chemotherapy. Results of the study by Chevillard et al. (1996) indicate a significant correlation between rapid induction of Pgp (rapid Pgp increase by 8 days after start of treatment) and both lower DFS and OS. Interestingly, this correlation was not statistically significant when a slower induction (by day 28) was considered. The neoadjuvant treatment in this study included an MDR1 substrate (anthracycline) in most cases (42/53).
The results of RT-PCR studies of MDR1 mRNA expression in the neoadjuvant setting are inconsistent and overall fail to support a correlation between higher pre-and posttreatment MDR1 mRNA levels and clinical resistance to chemotherapy.
In one study considering the relationship between pretreatment MDR1 mRNA and clinical response, a significantly higher response rate was observed in MDR1 − (22/35) than in MDR1 + (4/15) cases, following treatment with four cycles of an anthracycline-containing regimen (cyclophosphamide, 5-fluorouracil, doxorubicin) (Chevillard et al. 1996) . In contrast, MDR1 expression was not predictive of the response to treatment with a combination of cyclophosphamide, 5-fluorouracil and thiotepa (none of which is an MDR1 substrate). These data suggest a direct role for Pgp in affecting response to chemotherapy (Chevillard et al. 1996) . Wang et al. (1997) observed that MDR1 detection by RT-PCR predicted the response to tamoxifen but not to chemotherapy with doxorubicin. Arnal et al. (2000) did not observe any significant correlation between RT-PCR detected pre-treatment MDR1 mRNA levels and clinical response rate in 40 patients.
As for the MDR1 mRNA expression following treatment, in the study by Schneider et al. (2001) , clinical response rates following treatment with anthracyclinecontaining regimens were paradoxically somewhat higher for MDR1 + (18 responses out of 22, including two CRs) than for MDR1 − cases (15 responses out of 23, with no CRs). The study by Arnal et al. (2000) shows no association between post-treatment MDR1 mRNA expression and clinical response, nor between MDR1 mRNA expression and DFS and OS, following neoadjuvant treatment with 5-fluorouracil, doxorubicin and cyclophosphamide. These results are essentially confirmed by the outcome of the study of Faneyte et al. (2001) who observed no significant difference in MDR1 mRNA levels between 12 responders and 11 non-responders.
Chemotherapy in metastatic breast cancer
Ten studies evaluated the prognostic impact of different factors in breast cancer, included the evaluation of Pgp in metastatic/recurrent cancers (Verrelle et al. 1991 , Hennequin et al. 1993 , Decker et al. 1995 , Linn et al. 1995 , Schneider & Romero 1995 , Seymour et al. 1995 , Gregorcyk et al. 1996 , Buser et al. 1997 , Chevillard et al. 1997 , Linn et al. 1997 . Taken together, these studies include 162 metastatic and/or recurrent (mostly metastatic) cases, some of whom had previously been treated with chemotherapy. Ninety-three (57%) of these cases resulted positive for Pgp/MDR1, 91/156 at the protein and two of six at the mRNA level. Only one study (Seymour et al. 1995) , included more than 12 metastatic patients. In this study, Pgp expression was detected in 56/ 101 (55%) of metastatic or recurrent patients, a minority of whom had previously been treated with tamoxifen with or without adjuvant chemotherapy. Following treatment with chemotherapy (mostly containing MDR1 substrates), there 58 www.endocrinology.org was no apparent difference in response rates and survival in Pgp + and Pgp − patients. Of the other, smaller studies considering metastatic patients, three (Verrelle et al. 1991 , Schneider & Romero 1995 , Buser et al. 1997 detected Pgp in all cases, and two (Chevillard et al. 1997 , Linn et al. 1997 in none. Among the remaining, Cox proportional hazard regression analysis of the data from Gregorcyk et al. (1996) suggests a 5-year recurrence-free survival of 57% in stage IV Pgp − patients vs 2% in stage IV Pgp + patients. It has to be noted, however, that these conclusions are based on four metastatic patients, two of whom are Pgp + and two Pgp −. Overall, there are no grounds to support a significant impact of Pgp, by itself, on the prognosis and response to chemotherapy of metastatic patients.
Pgp expression and response to endocrine therapy Linn et al. (1995) , measured Pgp expression before treatment and found that early breast cancer patients treated with tamoxifen had a 3-year survival of 27% in five Pgp + cases, and 85% in 15 Pgp −. Another study (Keen et al. 1994) evaluated the correlation between Pgp immunostaining, before and after a 3-month treatment with tamoxifen (prior to locoregional treatment), and response rates in 43 patients, aged over 70. Patients whose tumors did not express Pgp after treatment were significantly more likely to respond to tamoxifen, response rates being 85% (22/26) in Pgp − vs 35% (6/ 17) in Pgp + cases. Differences in response rate based on Pgp expression before tamoxifen treatment were less striking and statistically not significant. Pre-treatment expression of MDR1 mRNA, as detected by RT-PCR, but not IHC detection of Pgp, appeared to correlate significantly with response to tamoxifen treatment in 15 locally advanced breast cancers (Wang et al. 1997) . Since Pgp does not confer resistance to tamoxifen (Clarke et al. 1992) , and tamoxifen, although an inhibitor of the MDR1 phenotype (Leonessa et al. 1994) , is not effluxed by Pgp (Callaghan & Higgins 1995) in in vitro models, it is unclear whether and how Pgp may have a causal role in resistance to tamoxifen.
Binding and transport by Pgp has been demonstrated in vitro for several steroids (Qian & Beck 1990 , Wolf & Horwitz 1992 , van Kalken et al. 1993 . Moreover, several steroids and steroid derivatives appear to reverse the multidrug resistance conferred by Pgp, possibly by a competitive mechanism (Naito et al. 1989 , Yang et al. 1989 , Hu et al. 1991 , Abraham et al. 1993 , Zalcberg et al. 1993 , Yang et al. 1994 , Gruol & Bourgeois 1997 , Tansan et al. 1997 , Leonessa et al. 2002 . Among steroids (and derivatives), glucocorticoids generally represent good substrates, while progesterone, medroxyprogesterone acetate, testosterone and androstenedione are poor substrates ). Pgp's role in the clinical resistance to steroidal agents has been explored in one study: the results show no correlation between Pgp expression before treatment and response rate and survival of patients with metastatic disease treated with different endocrine therapies, including gestagens and testosterone (Seymour et al. 1995) . As in most other instances, the study was not specifically aimed at investigating the role of Pgp in resistance to hormonal treatments, and included only 20 patients treated with gestagens and six with testosterone.
Correlation of clinical Pgp expression with in vitro chemosensitivity
Studies relating in vitro drug resistance of primary breast cancer cell cultures to MDR1/Pgp expression are few and heterogeneous for both models and methodological approach. Nonetheless, the results obtained in these studies consistently show a correlation between Pgp expression and in vitro resistance to the MDR1 anticancer substrate doxorubicin, and are supportive of a functional role of Pgp in clinical drug resistance. Salmon et al. (1989) used IHC to evaluate the levels of Pgp expression in 35 breast cancer specimens. Chemosensitivity was evaluated by an anchorage-independent clonogenic assay on primary cultures from 13 cancers, and defined as a reduction of the clonogenic efficiency of untreated controls to less than 50% following treatment with 0.1 µg/ml doxorubicin. Resistance to doxorubicin was observed in two out of eight (20%) Pgp− and five out of five (100%) Pgp + cases. This study also included 13 cases of lymphoma and myeloma. When all the cases were considered, the correlation between Pgp staining and in vitro resistance to doxorubicin was statistically significant. IHC was used also by Veneroni et al. (1994) . A significant association was observed between Pgp expression of 39 breast cancers and their in vitro drug resistance, as measured by [ 3 H]uridine incorporation. Sanfilippo et al. (1991) analyzed Pgp expression in 35 breast cancers using Western blotting. Chemosensitivity was defined in terms of inhibition of [ 3 H]thymidine incorporation into tissue fragments from different areas of the tumors. Single drug concentrations were used, and 20% inhibition of incorporation was used as the cut-off to define sensitivity or resistance. In this study, a comparatively high fraction of samples was classified as resistant, perhaps because the cytotoxic drugs were tested at relative concentrations. Resistance to doxorubicin was observed in ten out of ten Pgp + and in 17/25 Pgp− cases. Ten out of ten Pgp + and 19/25 Pgp− cases were classified as resistant to vincristine. Simultaneous resistance to both drugs was observed in all ten Pgp + cases and in 14/25 Pgp− cases.
A thymidine incorporation endpoint was also used by Mechetner et al. (1998) in the largest study of the kind published to date. A significant inverse correlation between www.endocrinology.org levels of Pgp expression, as defined by IHC, and the intensity of inhibition of thymidine incorporation, was observed for the MDR1 substrates doxorubicin (171 cases) and paclitaxel (131 cases), but not for 5-fluorouracil (164 cases), which is not an MDR1 substrate.
Finally, using an anchorage-dependent clonogenic assay for the evaluation of resistance to doxorubicin, Keith et al. (1990) observed a non-significant correlation between doxorubicin IC50 and the level of MDR1 mRNA expression in cell cultures from 14 breast cancer biopsies.
Clinical reversal of the MDR1 phenotype
The results of clinical trials of MDR1-reversing agents in drug-resistant breast cancer are summarized in Table 11 and are reviewed here with a focus not on the efficacy of the test agents, but as a possible proof of principle for Pgp's causative role in breast cancer's clinical drug resistance. Most of these studies are represented by 'cross-over' trials, whereas patients refractory to a specific treatment are then treated again with the same treatment, but with the addition of an MDR1-reversing agent. Two are randomized studies.
Verapamil has been the drug most widely investigated as an MDR1 − reversing agent in breast cancer. Results of a single randomized study (48 patients) showed no difference in response rate following treatment with epirubicin with and without verapamil (Mross et al. 1993 ). However, a small, but positive number of objective responses were consistently observed in four different cross-over trials, where verapamil (mostly R-verapamil) was added to anthracycline-containing regimens. Response rates of 17% (4/23) and 14% (2/14) were respectively reported in the cross-over arms by Lehnert et al. (1998) and by Thurlimann et al. (1995) following treatment with a combination of R-verapamil and epirubicin. A similar result, with a response rate of 10% (2/20) was observed by Warner et al. (1998) , who used a regimen that included R-verapamil and a variety of anthracyclines. Taylor et al. (1997) treated 27 advanced breast cancer patients, refractory to a regimen of cyclophosphamide, vincristine, doxorubicin and dexamethasone, with the same regimen plus verapamil and quinine, obtaining a 19% (5/27) objective response rate. The results of a fifth verapamil trial are consistent with the others (3/16 responses), but their interpretation is uncertain because of a flawed cross-over design: in this trial, anthracycline-resistant patients where treated with verapamil and doxorubicin, but also with vincristine (Ries & Dicato 1991) . Overall, when the data from the first four studies are pooled, verapamil appears to re-sensitize 15% (13/84) of advanced breast cancer patients refractory to anthracycline-containing regimens. By comparison, the response rate to an alternative second-line chemotherapy in patients already exposed to doxorubicin is about 21% (Henderson 1987) . Ries & Dicato (1991) Anthracycline-resistant patients 16 Dox, Vcr + verapamil RR = 3/16 Mross et al. (1993) Randomized 48 Epirub ± verapamil No difference in RR and survival Thurlimann et al. (1995) Cross-over 14 Eprib + R-verapamil RR = 2/14** Taylor et al. (1997) Cross-over 27 CVAD + verapamil and RR = 5/27 quinine Lehnert et al. (1998) Cross-over 23 Epirub + R-verapamil RR = 4/23 Warner et al. (1998) Cross-over 20 Anthracycline + R-verapamil RR = 2/20 Belpomme et al. (2000) Anthracycline-resistant patient 99 Vds/FU RR = 5/47 Vds/FU + verapamil RR = 14/42*** Bates et al. (1995) Patients generically refractory 33 Dox or Vbl + amiodarone RR = 9/33 to chemotherapy van Kalken et al. (1991) Cross-over 5 Epirub or Dox + bepridil RR = 0/5 Wishart et al. (1994) Randomized 213 Epirub and No difference in RR Prdnsl + quinidine and survival Toppmeyer et al. (2002) Cross-over 35 Paclitaxel + biricodar RR = 4/35 Murren et al. (1996) Anthracycline-refractory patients 16 Vbl + trifluoperazine RR = 1/6 RR, response rate. *First-line: anticancer agents; second line: MDR1-reversing agent. CVAD, cyclophosphamide, vincristine, adriamycin and dexamathasone; Dox, doxorubicin; epirub, epirubicin; Vbl, vinblastine; Vcr, vincristine; Prdnsl, prednisolone; FU, fluorouracil. **Data from this study may have been included in the subsequent paper by Lehnert et al. (1998) . ***P = 0.04.
In a second randomized study (213 patients), quinidine failed to improve the response to a combination of epirubicin and prednisolone (Wishart et al. 1994) . Another MDR1 − reversing agent, biricodar, when added to paclitaxel, obtained a partial response in 4/35 (11%) patients with locally advanced or metastatic disease refractory to paclitaxel (Toppmeyer et al. 2002) . A study by Bates et al. (1995) reported a 27% (9/33) response rate to amiodarone (chemosensitizer) in combination with doxorubicin or vinblastine. However, patients in this study were selected for a generic resistance to chemotherapy, as opposed to a specific resistance to respectively doxorubicin and vinblastine. In two more cross-over studies, bepridil and trifluoperazine were ineffective in sensitizing breast cancer patients to respectively epirubicin or doxorubicin (response rate = 0/14), and vinblastine (response rate = 1/16).
MRP1 and breast cancer
Expression in normal breast and in breast cancer, effect of treatment and association with other markers
MRP1 is readily detected by both RT-PCR and IHC in both normal breast and breast cancer (Table 12 ). In a study by Dexter et al. (1998) , MRP1 mRNA was detected by RT-PCR in the normal tissues adjacent to all of 55 breast cancers examined. Using IHC, Linn et al. (1997) found MRP1 expression in the epithelial component, but not in the stroma, of three of six normal breast samples. Ito et al. (1998) reported that MRP1 60 www.endocrinology.org mRNA levels, detected by RT-PCR, were significantly higher in breast cancer than in normal breast tissues.
MRP1 mRNA was detected by RT-PCR in 98% (429) of 437 untreated breast cancers (data pooled from six studies). In five out of these six studies MRP1 was detected in 100% of cases (Table 12) . When an IHC approach was used, MRP1 was detected, overall, in 49% of cases (213/432, across five studies) (Table 12 ). In one of these studies (Dexter et al. 1998) , MRP1 was detected in all 20 cases.
There is no convincing evidence of a correlation between MRP1 expression and tumor size, lymph node status and metastatic status, histological grade and type, ER and PgR status, age and menopausal status. Three studies used IHC to address the correlation between MRP1 tumor size. No correlation was found in the study by Nooter et al. (1997a) : MRP1 was found to be expressed in 23/76 (30%) T1, 50/148 (34%) T2, and in 12/33 (36%) T3 tumors. Filipits et al. (1999) observed no significant difference in T stage distribution between 20 MRP1 − and 80 MRP1 + primary breast cancer patients. However, MRP1 was detected more often in operable primary (16/20) than in locally advanced cancers (two of ten before neoadjuvant treatment) in the study by Linn et al. (1997) . In an isolated RT-PCR study, there was no correlation between T stage and MRP1 mRNA expression (Kanzaki et al. 2001) .
No correlation was observed between MRP1 protein (Nooter et al. 1997a , Filipits et al. 1999 or mRNA (Lacave et al. 1998 , Kanzaki et al. 2001 lesion and lymph node status. Zochbauer- Muller et al. (2001) observed a higher MRP1 protein staining intensity in lymph nodes than in their corresponding primary tumors. Four studies evaluated MRP1 expression in metastatic and non-metastatic patients, but the number of metastatic patients involved was always small. Filipits et al. (1996) , detected strong MRP1 staining in 12/57 non-metastatic and in three out of four metastatic patients. Linn et al. (1997) detected MRP1 in one out of five metastatic patients vs two out of ten in the locally advanced (untreated) and 16/ 20 in operable primary setting. In the RT-PCR study by Dexter et al. (1998) , only four patients were metastatic: the average level of MRP1 mRNA was apparently lower in these patients than in less advanced cases, but the difference was not statistically significant. Using RT-PCR, Kanzaki et al. (2001) observed no statistically significant difference in metastatic involvement between 21 MRP1 + and 22 MRP1− cases.
expression in the primary
In most cases (Filipits et al. 1996 , Dexter et al. 1998 , Lacave et al. 1998 , Ferrero et al. 2000 , no correlation was observed between MRP1 expression, at either the www.endocrinology.org protein or mRNA level, and histological grade. However, in one study significantly higher levels of MRP1 mRNA were reported by Beck et al. (1998) in grade 2 than in grade 3 cancers.
Two studies evaluating the correlation between MRP1 expression and ER and PgR expression found opposite trends, although correlations were not statistically significant in either study (Dexter et al. 1998 , Filipits et al. 1999 . A third study, with 43 patients, by Kanzaki et al. (2001) found no correlation between MRP1 mRNA levels and ER and PgR status.
No correlation was observed between MRP1 expression and age (Nooter et al. 1997a , Dexter et al. 1998 , Lacave et al. 1998 , Filipits et al. 1999 , Kanzaki et al. 2001 , menopausal status (Filipits et al. 1996 , Nooter et al. 1997a , and histological type (Dexter et al. 1998 , Lacave et al. 1998 , Filipits et al. 1999 .
A correlation between MRP1 and MDR1 mRNA expression has been reported in two studies (Beck et al. 1998 , Kanzaki et al. 2001 , but not in a third (Lacave et al. 1998) . No correlation was found at the level of protein expression (Filipits et al. 1996) . A direct correlation has been observed between MRP1 and the expression of drugresistance proteins LRP (Beck et al. 1998) and GSTB (Lacave et al. 1998) . Single studies have also reported a direct correlation between the expression of MRP1 and PKCη (Beck et al. 1998) , and an inverse correlation with the cancer S-phase fraction (Ferrero et al. 2000) .
Only in one study was the effect of chemotherapy on MRP1 expression considered. Using IHC, Linn et al. (1997) detected MRP1 respectively in two of ten (20%) and in 9/16 (56%) locally advanced breast cancer cases before and following neoadjuvant chemotherapy with an anthracycline-containing regimen. The results, although limited by the low number of cases, suggest an inducing effect of treatment, similar to that observed for MDR1/Pgp expression.
MRP1 expression and prognosis
The effect of MRP1 expression on the short-term response to chemotherapy was considered in two small studies. Linn et al. (1997) observed no correlation between pre-treatment MRP1 protein expression and the pathological response of locally advanced cancers to a neoadjuvant regimen including doxorubicin and cyclophosphamide. Only two of the cases were MRP1 +. The second study, by Nooter et al. (1997b) , evaluated the impact of MRP1 expression on the prognosis and response to chemotherapy of recurrent breast cancer. In previously untreated patients, the presence of MRP1 protein was associated with a lower response rate (one of eight in MRP + cases vs 6/15 in MRP− cases). No association between MRP1 and response rate was observed in patients who had already been treated with chemotherapy previously. This paper does not specify the anticancer drugs used in the study.
A correlation of MRP1 expression with survival parameters appears to be supported by the results of most, but not all studies. Relapse-free survival and OS were reported to inversely correlate with MRP1 protein expression by both Filipits et al. (1999) and Nooter et al. (1997a) . Filipits et al. observed MRP1 expression in 80% of 100 nonmetastatic cases: MRP1 expression correlated with shorter OS (statistically significant) and DFS (nearly significant), but results were not analyzed in relation to treatment. In the study by Nooter et al., MRP1 expression was associated with an increased risk for failure in the subgroups of patients with T1 cancers, with node-negative cancers and with node-positive cancers treated with CMF (as opposed to node-positive patients receiving hormonal or no adjuvant treatment). Similarly, the risk of death correlated with MRP1 expression in T1 cancer, and in N + cancers treated with CMF. In another study by Nooter et al. (1997b) , previously untreated relapsed patients whose cancers were MRP + had a shorter time to disease progression.
Two studies out of three reported no correlation between MRP1 mRNA expression (evaluated using RT-PCR) and prognosis. Ferrero et al. (2000) observed no correlation between MRP1 mRNA levels and progressionfree survival and OS of patients treated with anthracyclinecontaining adjuvant regimens. Similarly, Kanzaki et al. (2001) observed no correlation between MRP1 mRNA expression and relapse after adjuvant treatment with doxorubicin. However, in a study by Ito et al. (1998) , including 27 patients, an increased risk of relapse in the 10 years following adjuvant chemotherapy (mostly including mitomycin C) was observed in patients whose primary tumors expressed higher levels of MRP1 mRNA.
Overall the above studies appear to indicate a trend for a correlation between early expression of MRP1 protein and a worse prognosis. As in the case of Pgp, and even more so, the question of a direct causal role of MRP1 on drug resistance remains open.
Functional assessment of Pgp and MRP1 in breast cancers by technetium-99m radiopharmaceuticals
99m Tc-sestamibi and 99m Tc-tetrofosmin are two lipophilic 99m Tc-labeled agents originally used for the evaluation of myocardial perfusion (Wackers et al. 1989 , Maddahi et al. 1991 . These agents are also used for the scintigraphic detection of malignant tissues, including breast and lung cancer and sarcomas (Hassan et al. 1989 , Caner et al. 1991 , Kostakoglu et al. 1998 , Berghammer et al. 1999 .
Studies carried out on cell lines, in vitro and in vivo, have shown that both agents are substrates for both Pgp and MRP1, but not for BCRP/MXR, another ABC protein able to confer 62 www.endocrinology.org a multidrug-resistant phenotype (Piwnica-Worms et al. 1993 , Ballinger et al. 1995 , Barbarics et al. 1998 , Hendrikse et al. 1998 , Chen et al. 2000 .
Several clinical studies have confirmed an inverse correlation between the tumor/background ratio or fractional retention of both 99m Tc-sestamibi and 99m Tc-tetrofosmin and Pgp expression in human breast cancer (Del Vecchio et al. 1997 , Kostakoglu et al. 1998 , Yoon et al. 1999 , Sun et al. 2000 , Cayre et al. 2002 , Mubashar et al. 2002 . In one study, the maximum inverse correlation with 99m Tc-sestamibi accumulation was observed in cancers that expressed both Pgp and MRP1 (Kao et al. 2001) .
If Pgp and MRP1 play a role in breast cancer resistance to chemotherapy, the accumulation/wash-out of 99m Tcsestamibi and 99m Tc-tetrofosmin at the tumor level should be predictive of clinical responsiveness to anticancer drugs that are Pgp and/or MRP1 substrates. Ciarmiello et al. (1998) observed pathological responses (described as the absence of any macroscopic and microscopic evidence of disease) to a neoadjuvant treatment with epirubicin in only 2/17 (12%) breast cancer patients showing a rapid clearance of 99m Tcsestamibi from their tumors (i.e. decreased tumor retention), as compared with 14/22 (64%) patients whose tumors exhibited prolonged retention. Similarly, in a study by Cayre et al. (2002) , including 45 patients, a negative 99m Tcsestamibi scintimammography predicted resistance to anthracycline-containing neoadjuvant chemotherapy, as evaluated in terms of both clinical and pathological response. Alonso et al. (2002) observed that tumor/background tissue uptake ratios of 99m Tc-sestamibi were significantly higher in 43 patients who responded than in six patients who did not respond to treatment with fluorouracil, doxorubicin and cyclophosphamide. Tumor retention of 99m Tc-tetrofosmin appears to be predictive of breast cancer response to chemotherapy as well - Takeuchi et al. (2002) observed response rates of 77% (10/13) in breast cancer patients with high retention, but of only 8% (1/12) in patients with low retention of 99m Tc-tetrofosmin, following treatment with a polychemotherapy regimen including an anthracycline.
There are two reasons why scintigraphic evaluation of the tumor retention of technetium-99m substrates of Pgp may be expected to be more predictive of clinical drug resistance than just the evaluation of Pgp expression. First, retention/ wash-out of these substrates provides a measure of function which is not provided by expression studies. Pgp might be expressed without necessarily being functional, although the studies mentioned show a good correlation between Pgp expression and technetium-99m complex retention. Secondly, it is evident that both 99m Tc-sestamibi and 99m Tctetrofosmin represent substrates not only for Pgp, but also for MRP1. Indeed expression of both proteins appears to inversely correlate with tumor retention better than expression of either protein by itself (Kao et al. 2001) . That these agents may also be substrates for other transporters cannot be excluded at present. Retention of technetium-99m tracers may actually provide a measure of the cumulative function of different transporters involved in cancer drug resistance.
Overall, the available evidence on the relationship between retention of 99m Tc-sestamibi and of 99m Tctetrofosmin and response to chemotherapy is consistent with a role of Pgp and MRP1 as factors in breast clinical drug resistance. A more convincing assessment of the role of each transporter will be provided by use of scintigraphic substrates that are more specific for each transporter. For example, leukotrienes are more specific substrates for MRP proteins and could be used, in an 'inactivated' form, to more specifically image MRP1 and MRP2 function. Other substrates, that are more specific for Pgp, may be represented by [
11 C]colchicine and [
11 C]verapamil (Hendrikse et al. 1999) .
Conclusions
Since 1997 Pooling the results of older and more recent studies essentially confirms the effect of previous chemotherapy on Pgp expression, reported in our earlier meta-analysis (Trock et al. 1997) . Overall, IHC detects Pgp in 52% of cancers previously treated with anticancer drugs that are MDR1 substrates (vs 40% in the untreated cases). This effect is evident in recently treated (Pgp expression rate: 56%), but not in remotely treated patients (expression rate: 36%). There appears to be no overall increase in Pgp expression rate (37%) in the pool of cases whose treatment was either undefined or did not include MDR1 substrates. The effect of chemotherapy is particularly striking when Pgp expression is evaluated in the same cancers before and after chemotherapy in a neoadjuvant setting. Pooled data show expression rates of respectively 43 and 64%, with an induction rate (percentage of cases turning from negative to positive) of 37%. Similar evaluations by RT-PCR demonstrate an induction rate of 45% (from 50% before to 73% after treatment with Pgp substrate-containing regimens). At least one study suggests a similarly inducing effect of chemotherapy on MRP1 expression.
Is this effect of chemotherapy on Pgp expression the result of a true induction or of a selective mechanism? Since increased expression is more evident following treatment with drugs that are MDR1 substrates, a selective effect is certainly possible. However, the lower expression of Pgp in remotely treated cancers suggests that the increased expression that follows treatment is a transient effect. Moreover, the results of at least one study demonstrate an increase in MDR1 mRNA expression following both an MDR1 substrate-containing and an MDR1 substrate-devoid neoadjuvant chemotherapeutic regimen (Chevillard et al. 1996) . In this study, the only difference between the two regimens was that the induction appeared slower in the presence of the MDR1 substrate. This non-specific induction may represent a confirmation at the clinical level of the ability of different kinds of 'stress' stimuli to induce MDR1 expression, which has already been observed in several in vivo and in vitro models (Chin et al. 1990 , Fairchild & Cowan 1991 , Miyazaki et al. 1992 , Chaudhary & Roninson 1993 , Uchiumi et al. 1993a ,b, Ohga et al. 1998 , Hu et al. 1999 , 2000 , Stein et al. 1999 .
A similar inducing effect of chemotherapy has also been reported for MRP1 (Ishikawa et al. 1996 , Linn et al. 1997 . The data reviewed in this paper appear to confirm that, in breast cancer, the expression of the mutant form of p53, a well-known factor in stress-induced cell response (Soussi 2000) , correlates with Pgp expression. In the study by Chevillard et al. (1996) , the correlation of a more rapid increase in Pgp/MDR1 levels with clinical drug resistance appears to further support an induction effect. Finally, while the overall available data seem to support an induction phenomenon, it is still possible that selection of Pgp + cells by anticancer drugs is also involved.
Correlations of Pgp expression with other clinical and pathological parameters are much less compelling. There is no difference in the expression of either Pgp protein or mRNA between primary operable and locally advanced cancers, although there appears to be at least a trend to lower rates of Pgp protein expression in primary tumors smaller than 2 cm (T1). Small trends have also been reported for a correlation of lower MDR1 mRNA levels with aneuploidy (two out of three studies) and of higher levels with lobular carcinoma (two out of three studies). Overall, data are mixed, negative, or insufficient to support a correlation between Pgp and tumor grade, ER or PgR expression. Correlative data are, if anything, weaker for MRP1. Overall, the data do not support a correlation of MRP1 with tumor size, lymph node and metastatic status, histological grade and type, age, menopausal status, ER and PgR.
Several kinds of evidence appear to support a correlation between Pgp (and MRP1) and clinical drug resistance. Correlative studies based on IHC show an impact of Pgp expression on the long-term outcome of the treatment of both early (adjuvant setting) and locally advanced (neoadjuvant setting) breast cancer. In the neoadjuvant setting, the correlation between Pgp expression and short-term (response rates) and long-term (DFS and OS) treatment outcome is stronger when Pgp is detected after treatment. Data from one study suggest that rapid Pgp inducibility during treatment may be a more important predictor of drug resistance than post-treatment expression alone (Chevillard et al. 1996) . This kind of correlation cannot be discerned in the metastatic setting, partly due to the low numbers of cases considered and to data heterogeneity. It is also likely that the contribution of specific factors to drug resistance is more difficult to discriminate in more advanced stages, where drug resistance may be expected to involve a larger number of redundant mechanisms. Although fewer data are available about MRP1, results of correlative studies also appear to support a correlation between treatment outcome and MRP1 expression.
A correlation between Pgp and MRP1, and treatment outcome is further supported by the observed correlation between retention of 99m Tc-sestamibi (and 99m Tc-tetrofosmin), an indirect measure of Pgp and MRP1 activity, and clinical response rates. Pgp's role is supported as well by the results of ex vivo evaluations, which consistently (in five out of five studies) show a correlation between Pgp expression and in vitro resistance of breast cancers explants to the MDR1 substrate doxorubicin.
While a correlation between Pgp expression and treatment outcome appears relatively well defined, it is less clear that Pgp plays a significant role in directly causing clinical drug resistance. Imperfect trial design largely contributes to this lack of clarity. A direct mechanistic role of Pgp in causing clinical drug resistance would imply that the observed correlation with drug resistance is specific for MDR1 substrates. Results in this sense are insufficient and contradictory. Most of the correlative studies have been carried out only with treatments including Pgp substrates, in the absence of a control group treated without Pgp substrates. Only in three studies was such a control present. In two of these studies, one in the adjuvant and the other in the neoadjuvant setting, correlation of Pgp expression with a worse treatment outcome was observed in the presence of both kinds of treatment. Only in the third study was correlation with Pgp expression before neoadjuvant treatment specific for the subgroup of patients whose regimen included MDR1 substrates.
We also looked at clinical trials of MDR1 − reversing agents for a proof of principle of Pgp's role in causing drug resistance in breast cancer. The results of four out of four cross-over studies where verapamil was added to treatment consistently show a small, but positive response to anthracycline-containing regimens in anthracycline-refractory patients (average response rate = 15%). However, results were not evaluated in relation to the cancers' Pgp expression status and the effect reported in these studies may be due to pharmacokinetic interactions through drug-induced inhibition of www.endocrinology.org Pgp expressed in normal tissues, or through cross-reaction with P450 enzymes involved in anticancer drug metabolism (Harris et al. 1994 , Relling et al. 1994 , Fischer et al. 1998 , Kim et al. 1999 , Yao et al. 2000 . The cross-reactivity with other ABC proteins (such as MRP1 and MRP2/cMOAT) of most presently available MDR1 − reversing agents (Breuninger et al. 1995 , Davey et al. 1996 , Germann et al. 1997 further complicates the interpretation of trials of MDR1 reversal.
More and better-designed studies are needed to define whether Pgp, MRP1, and possibly other ABC proteins, play a significant role as causes of drug resistance, and consequently represent valid pharmacological targets in breast cancer.
The data we have reviewed here, as well as theoretical considerations, indicate that these studies should be preferably based on the use of methods for the in situ detection of protein expression (such as IHC). The need for standardization of methodology has been well described (Beck et al. 1996) : calibration of the detection method should be achieved through the use of well-characterized ABC proteinpositive cell lines and tissue positive and negative controls, as well as using adequate antibody controls. Detection by multiple antibodies should help increase the specificity of results. A major question which remains to be clarified is that of the definition of adequate 'cut-offs' for 'positivity'. The criteria used so far have been most heterogeneous, preventing an adequate comparison of the results of different studies. Adequate statistical criteria should be applied to define the size of the study populations, in order to achieve sufficient statistical power. Too many of the published studies include too small a number of cases. Future correlative studies evaluating the role of an ABC transporter protein should, if possible, compare the outcome of treatment according to the absence or presence of the target protein in cancers, and to the use of anticancer drugs that are or are not substrates for the protein. A causal role for the protein under investigation will be supported by evidence of a decreased efficacy of substrate drugs specifically in those cancers which express the protein. Functional studies, such as those based on the in vivo use of tracer substrates, should use agents specific for the target proteins, or use parallel evaluations of protein expression.
Ex vivo evaluations, based on the use of explants or primary cultures obtained from surgical specimens, may need to be further validated. These methods provide the theoretical advantage of controlled conditions in which drug toxicity and pharmacokinetics, and certain ethical issues, are not factors. While this approach has been used mostly in correlational studies, these experimental models might help to provide even stronger proof of principle if used as part of ex vivo trials of drug-resistance reversal. Proof of principle would be provided by evidence of chemosensitization which is specific in cultures/explants that express the target protein and are resistant to the protein substrates, and that is obtained using chemosensitizing agents that are specific for the protein.
The definitive proof of the relevance of an ABC protein or of any other mechanism as a cause of drug resistance will come from the evidence of drug-resistance reversal in clinical trials. The results will have to have the same characteristics of specificity (of protein expression, of anticancer drugs involved, and of chemosensitizer) just described for ex vivo trials. Where a quick answer is needed, a surrogate endpoint for the efficacy of treatment may be represented by scintimammographic evidence of increased tracer substrate retention in the presence of the chemosensitizer, keeping in due consideration the already mentioned limitations in the specificity of the substrates currently used (e.g.
99m Tc-sestamibi and 99m Tc-tetrofosmin). Indeed, 99m Tc-sestamibi imaging has already been used in the assessment of toremifene as a multidrug-resistance modulator in breast cancer (Mubashar et al. 2002) .
Finally, future studies will have to take into account the likely multifactorial nature of drug resistance. Studies carried out at an earlier stage might help to reduce the number of redundant mechanisms of resistance. But that may not be enough. For example, some studies suggest that Pgp's coexpression with p53 (Honkoop et al. 1998) in breast cancer or MRP1 in leukemia (Schuurhuis et al. 1995 , Kasimir-Bauer et al. 1998 better correlates with the response to chemotherapy than expression of Pgp alone. Identifying the role of Pgp or any other ABC protein may require that several other factors, including potentially redundant mechanisms of drug resistance, be taken into consideration in the course of the same evaluation. In the next years, proteomics and bioinformatics, with their ability to detect and interpret the complex correlations of a high number of proteins, should provide a valuable contribution in singling out those factors that are critical in clinical drug resistance. randomized study of paclitaxel versus cyclophosphamide/expressions in relation to technetium-99m
